Compare ECVT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECVT | AUPH |
|---|---|---|
| Founded | 1935 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2017 | 2014 |
| Metric | ECVT | AUPH |
|---|---|---|
| Price | $11.35 | $14.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $12.60 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 1.4M | 784.5K |
| Earning Date | 05-29-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $723,515,000.00 | $283,055,000.00 |
| Revenue This Year | $6.38 | $17.79 |
| Revenue Next Year | $6.78 | $15.50 |
| P/E Ratio | ★ N/A | $6.80 |
| Revenue Growth | 2.70 | ★ 20.38 |
| 52 Week Low | $5.24 | $6.83 |
| 52 Week High | $12.33 | $16.54 |
| Indicator | ECVT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 41.76 |
| Support Level | $8.04 | $11.05 |
| Resistance Level | $11.85 | $16.28 |
| Average True Range (ATR) | 0.40 | 0.48 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 30.00 | 43.49 |
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.